Previous studies have shown that juglone treatment reduces BCL-2 protein levels while increasing active caspase-3 levels in ovarian cancer SKOV3 and human breast cancer MCF-7 cells [12, 40]. This evidence concerns the gene CASP3 and breast carcinoma.